Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer. (4th December 2014)

• Record Type: Journal Article
• Authors: Woolen, Sean; Holzmeyer, Cameron; Nesbitt, Emily; Siami, Paul F.
• Other Names: Gulley James L. Academic Editor.
• Is Part Of: Prostate cancer. Volume 2014(2014)
• Publication Date: 2014-12-04
• Subjects: Prostate -- Cancer -- Periodicals; Prostate -- Cancer -- Surgery -- Periodicals; 616.99463
• DOI: 10.1155/2014/490315
• Languages: English
• ISSNs: 2090-3111

Abstract

Abstract : Objectives. Long-term assessment of the efficacy and tolerability of subcutaneous abdominal histrelin acetate implants that have been inserted for more than two years. Materials and Methods. Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant. Results. Following insertion of the first implant, 92.1% and 91.8% of patients had a serum testosterone level of ≤30 ng/dL at 24 and 48 weeks, respectively. Serum testosterone levels remained at <30 ng/dL for 96% of patients at two years and for 100% of patients at 3, 4, and 5 years. The testosterone levels remained significantly less than baseline ( P < 0.05 ) . Six patients (5.3%) had androgen-independent progression when followed up on the long term, increasing the mean serum PSA at 3, 4, and 5 years to 35.0 µ g/L ( n = 22 ), 30.7 µ g/L ( n = 13 ), and 132.9 µ g/L ( n = 8 ), respectively. The mean serum PSA was significantly greater than baseline during these years ( P < 0.05 ) . Eight patients (7.1%) experienced minor, but not serious, adverse events from the histrelin acetate. Conclusion. Subcutaneous abdominal histrelin acetate implants are an effective long-term and well-tolerated administration method for treating patients with advanced prostate cancer.